Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Solid Tumors 2Neoplasms 2Liposarcoma 2Glioblastoma 1

Interventions

Doxorubicin 14Radiotherapy 10Ifosfamide 10Trabectedin 7pazopanib 4Imatinib Mesylate 3Filgrastim 3Etoposide 3Cyclophosphamide 3Chemotherapy, Adjuvant 3temsirolimus 2romidepsin 2ribociclib 2pegfilgrastim 2eribulin 2cixutumumab 2brigimadlin 2belinostat 2Vincristine 2Sunitinib 2Radiotherapy, Conformal 2Gemcitabine 2Epirubicin 2Dexamethasone 2Dactinomycin 2Carboplatin 2soblidotin 1sitravatinib 1siremadlin 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Liposarcoma × brigimadlin × Clear all
NCT05218499 2026-03-02

Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 2/3 Completed
400 enrolled 15 charts
Sarcoma

Liposarcoma

NCT06058793 2026-01-09

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Boehringer Ingelheim

Phase 3 Completed
138 enrolled
Sarcoma

Liposarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡